The company said it saw record-setting growth in new products in fiscal 2018 with increasing reimbursement adding to its hereditary cancer business.
The firm's overall growth in the quarter was led largely by 9 percent growth in its Diagnostics and Genomics Group.
The company also said it launched a new comprehensive diagnostic called HeartCare for surveillance of heart transplant patients.
The decline was in line with what the company preliminarily reported last month, reflecting much lower collaboration revenues than in the prior year period.
The firm placed 65 sample-to-answer systems under contract in the second quarter compared to 35 systems in the prior-year quarter.
The company's life sciences segment had $1.08 billion in revenues, driven by strong performance of the preanalytical systems, diagnostic systems, and biosciences units.
The company said volumes for its Cologuard colon cancer screening test rose 59 percent to 215,000 during the quarter.
The firm's diagnostics division was up 4 percent. Molecular diagnostics grew 7 percent, cytology & perinatal was flat, and blood screening was down 2 percent.
Revenues for Roche Diagnostics totaled CHF 6.26 billion for H1, driven primarily by demand for immunodiagnostic solutions.
The company's revenues totaled $6.08 billion, up from $4.99 billion during Q2 of 2017.
Researchers hope to tease out the signature effects that different carcinogens leave on the genome to determine their contributions to disease, Mosaic reports.
The Wall Street Journal looks into the cost of new gene therapies.
An Imperial College London-led team reports that it was able to use a gene drive to control a population of lab mosquitos.
In PNAS this week: genomic effects of silver fox domestication, limited effect of mitochondrial mutations on aging in fruit flies, and more.